Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results

Context Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01), Zacks reports.Get Context Therapeutics alerts:Context Therapeutics Trading Up 1.8%Shares of CNTX traded up $0.02 during midday trading on Wednesday, hitting $1.13. 348,243 shares of the company traded hands, compared to its average volume of 495,297. The stock has a 50-day moving average of $1.06 and a 200-day moving average of $0.85. Context Therapeutics has a one year low of $0.49 and a one year high of $2.32. Wall Street Analysts Forecast GrowthA number of research firms have issued reports on CNTX. Guggenheim began coverage on shares of Context Therapeutics in a report on Thursday, September 18th. They set a "buy" rating and a $5.00 price objective on the stock. HC Wainwright cut their price target on shares of Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Context Therapeutics in a report on Wednesday, October 8th. D. Boral Capital reissued a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Thursday, October 16th. Finally, Cantor Fitzgerald initiated coverage on shares of Context Therapeutics in a report on Thursday, October 2nd. They issued an "overweight" rating on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $5.20.View Our Latest Research Report on CNTXAbout Context Therapeutics (Get Free Report)Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.Read MoreFive stocks we like better than Context TherapeuticsTrading Halts Explained3 Cash-Rich Stocks With High Growth Potential Right NowWhat Are Trending Stocks? Trending Stocks ExplainedWhy Vertical Aerospace Stock Could Double After This Flight TestHigh Flyers: 3 Natural Gas Stocks for March 2022Amazon: Breakout Confirmed—Here’s Where It Could Go NextThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Context Therapeutics Right Now?Before you consider Context Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.While Context Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here